MedTrace Logo

Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

NCT01213823 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 536

Last updated 2016-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin and/or micafungin.

Conditions

  • Invasive Candidiasis
  • Candidemia

Interventions

OTHER

Does not apply

This is a non-interventional study, therefore the intervention type / name do not apply

OTHER

Does not apply

This is a non-interventional study, therefore the intervention type / name do not apply

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213823 on ClinicalTrials.gov